JP6437523B2 - マクロライドならびにそれらの調製および使用の方法 - Google Patents

マクロライドならびにそれらの調製および使用の方法 Download PDF

Info

Publication number
JP6437523B2
JP6437523B2 JP2016506660A JP2016506660A JP6437523B2 JP 6437523 B2 JP6437523 B2 JP 6437523B2 JP 2016506660 A JP2016506660 A JP 2016506660A JP 2016506660 A JP2016506660 A JP 2016506660A JP 6437523 B2 JP6437523 B2 JP 6437523B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520551A (ja
Inventor
マイヤーズ，アンドリュー，ジー．
セイプル，イアン，バス
チャン，ツィーヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2016520551A publication Critical patent/JP2016520551A/ja
Application granted granted Critical
Publication of JP6437523B2 publication Critical patent/JP6437523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016506660A 2013-04-04 2014-04-04 マクロライドならびにそれらの調製および使用の方法 Active JP6437523B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361808441P 2013-04-04 2013-04-04
US61/808,441 2013-04-04
US201361832639P 2013-06-07 2013-06-07
US61/832,639 2013-06-07
US201461946604P 2014-02-28 2014-02-28
US61/946,604 2014-02-28
PCT/US2014/033025 WO2014165792A2 (en) 2013-04-04 2014-04-04 Macrolides and methods of their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018214091A Division JP6850783B2 (ja) 2013-04-04 2018-11-14 マクロライドならびにそれらの調製および使用の方法

Publications (2)

Publication Number Publication Date
JP2016520551A JP2016520551A (ja) 2016-07-14
JP6437523B2 true JP6437523B2 (ja) 2018-12-12

Family

ID=51659360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016506660A Active JP6437523B2 (ja) 2013-04-04 2014-04-04 マクロライドならびにそれらの調製および使用の方法
JP2018214091A Active JP6850783B2 (ja) 2013-04-04 2018-11-14 マクロライドならびにそれらの調製および使用の方法
JP2020088633A Active JP7111381B2 (ja) 2013-04-04 2020-05-21 マクロライドならびにそれらの調製および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018214091A Active JP6850783B2 (ja) 2013-04-04 2018-11-14 マクロライドならびにそれらの調製および使用の方法
JP2020088633A Active JP7111381B2 (ja) 2013-04-04 2020-05-21 マクロライドならびにそれらの調製および使用の方法

Country Status (11)

Country Link
US (3) US9982005B2 (enExample)
EP (2) EP2988597B1 (enExample)
JP (3) JP6437523B2 (enExample)
KR (2) KR102363621B1 (enExample)
CN (2) CN111825733A (enExample)
AU (3) AU2014248014B2 (enExample)
BR (1) BR112015025159A2 (enExample)
CA (2) CA3130061C (enExample)
IL (1) IL241878B (enExample)
MX (2) MX377459B (enExample)
WO (1) WO2014165792A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
AU2014248014B2 (en) 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3211997A4 (en) * 2014-10-08 2018-10-24 President and Fellows of Harvard College 14-membered ketolides and methods of their preparation and use
SG11201707215XA (en) * 2015-03-06 2017-10-30 Cempra Pharmaceuticals Inc Processes for preparing fluoroketolides
CA2978670A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Synthesis of desosamines
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
GB201608236D0 (en) * 2016-05-11 2016-06-22 Fidelta D O O Seco macrolide compounds
SG11201908454TA (en) * 2017-02-17 2019-10-30 Cempra Pharmaceuticals Inc Triazole-containing macrolides and ophthalmic uses therefor
US11673910B2 (en) 2017-04-28 2023-06-13 Zikani Therapeutics, Inc. Macrolides with modified desosamine sugars and uses thereof
SG11202105227QA (en) 2018-11-19 2021-06-29 Zikani Therapeutics Inc C10-alkylene substituted 13-membered macrolides and uses thereof
IL283185B2 (en) * 2018-11-19 2024-06-01 Zikani Therapeutics Inc Macrolides with 13 members converted to C10-cyclic and their uses
CN114591286B (zh) * 2021-04-12 2023-05-23 南京大学 新型大环内酯化合物acautalides A-C及其制备方法和应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
FR2692579B1 (fr) * 1992-06-19 1995-06-02 Roussel Uclaf Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
AU6082594A (en) 1993-01-11 1994-08-15 Merck & Co., Inc. 8a-aza and 9a-aza macrolide antibiotics, and a process for producing same and methods of use
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
JP3652394B2 (ja) * 1995-01-27 2005-05-25 高砂香料工業株式会社 Ｎ−置換−７−アミノ−５−ヒドロキシ−３−オキソヘプタン酸誘導体およびその製造法
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
HN1998000074A (es) * 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
AU7986098A (en) * 1997-06-27 1999-01-19 Merck & Co., Inc. 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
HN1998000159A (es) * 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
JP2002542197A (ja) 1999-04-16 2002-12-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ケトライド抗菌剤
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
HRP990116B1 (en) 1999-04-20 2007-10-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. NOVEL 8a AND 9a- 15-MEMBERED LACTAMES
OA11945A (en) 1999-05-24 2006-04-13 Pfizer Prod Inc 13-Methyl erythromycin derivatives.
AU6316400A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU6748500A (en) 1999-08-24 2001-03-19 Abbott Laboratories 9a-azalides with antibacterial activity
NZ518665A (en) 2000-01-27 2005-02-25 Pfizer Prod Inc Azalide antibiotic compositions
JP4596591B2 (ja) 2000-03-09 2010-12-08 塩野義製薬株式会社 ８ａ−オキサホモエリスロマイシン誘導体、製造方法、合成中間体および医薬組成物
US6440942B1 (en) 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
RU2004117082A (ru) 2001-12-05 2005-04-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Кетолидные 6-0-ацил-производные эритромицина в качестве антибактериальных средств
US8063021B2 (en) 2002-01-17 2011-11-22 Kosan Biosciences Incorporated Ketolide anti-infective compounds
RU2330069C2 (ru) * 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
JPWO2004065346A1 (ja) 2003-01-21 2006-05-18 住友化学株式会社 （−）−テトラヒドロリプスタチンおよびその中間体の製造方法
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
CN1530079A (zh) 2003-03-13 2004-09-22 钱本文 中空分叉髓内钉
HRP20030381B1 (en) 2003-05-14 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
EP1794171A2 (en) 2004-07-28 2007-06-13 Ranbaxy Laboratories, Ltd. Ketolide derivatives as antibacterial agents
US7767797B1 (en) 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
US20090170790A1 (en) 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
US20060096158A1 (en) 2004-11-08 2006-05-11 Robinson J M Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same
CN101103039A (zh) 2005-01-12 2008-01-09 阿尔法马股份公司 作为抗菌剂的红霉素衍生物
EP1841775A2 (en) 2005-01-12 2007-10-10 Alpharma APS Erythromycin derivatives as antibacterial agents
CN101142225B (zh) 2005-01-13 2011-09-07 葛兰素集团有限公司 具有抗炎活性的大环内酯
EP1879903A1 (en) * 2005-05-10 2008-01-23 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Ether linked macrolides useful for the treatment of microbial infections
CN101228171A (zh) 2005-07-26 2008-07-23 默克勒有限公司 作为5-脂氧化酶和环加氧酶抑制剂的吡咯里嗪和中氮茚化合物的大环内酯偶联物
WO2007034909A1 (ja) * 2005-09-22 2007-03-29 Kaneka Corporation （３ｒ，５ｒ）－７－アミノ－３，５－ジヒドロキシヘプタン酸誘導体の製造法
EP1935893A4 (en) * 2005-10-13 2009-07-22 Eisai R&D Man Co Ltd TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D
JP5015016B2 (ja) 2006-02-07 2012-08-29 大正製薬株式会社 １０ａ−アザライド化合物
AU2008224633A1 (en) 2007-03-13 2008-09-18 Pfizer Products Inc. Erythromycin-based macrolides
DE102007046388A1 (de) * 2007-09-21 2009-09-10 Universität Hamburg Entwicklung eines Bindungsassays und Darstellung neuartiger Inhibitoren des Myelin Assoziierten Glycoproteins
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
KR100980379B1 (ko) * 2008-04-02 2010-09-06 주식회사 파마코스텍 광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법
WO2010015703A2 (en) 2008-08-07 2010-02-11 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Novel 6-o-substituted 15-membered 8a- and 9a-lactams
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
JP5662445B2 (ja) 2009-08-13 2015-01-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 新規マクロライド及びその使用
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
WO2011131749A1 (en) 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
KR101945324B1 (ko) 2010-05-20 2019-02-07 셈프라 파마슈티컬스, 인크. 매크로라이드들 및 케톨라이드들과 이의 중간체들을 제조하는 공정들
WO2012001089A1 (en) 2010-07-01 2012-01-05 Novartis Ag Antibiotic compositions
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
US8796474B1 (en) 2010-08-23 2014-08-05 Rutgers, The State University Of New Jersey Macrolide compounds and methods and intermediates useful for their preparation
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012051126A2 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
NZ610547A (en) * 2010-11-16 2015-07-31 Merial Ltd Novel monensin derivatives for the treatment and prevention of protozoal infections
WO2012127351A1 (en) 2011-03-22 2012-09-27 Wockhardt Limited Process for preparation of ketolide compounds
CN102690297A (zh) 2011-03-22 2012-09-26 连云港海康生物科技有限公司 一种壳寡糖季铵盐及其合成方法
JP6023192B2 (ja) 2011-07-01 2016-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状インスリン分解酵素（ｉｄｅ）阻害剤およびその使用
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
AU2014248014B2 (en) 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
EP3211997A4 (en) 2014-10-08 2018-10-24 President and Fellows of Harvard College 14-membered ketolides and methods of their preparation and use
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
CA2978670A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Synthesis of desosamines

Also Published As

Publication number Publication date
AU2020281043A1 (en) 2021-01-07
CA3130061C (en) 2024-05-28
US10913764B2 (en) 2021-02-09
AU2019200494B2 (en) 2020-09-17
AU2020281043B9 (en) 2023-02-09
JP2020169174A (ja) 2020-10-15
US9982005B2 (en) 2018-05-29
AU2019200494A1 (en) 2019-02-14
AU2014248014B2 (en) 2018-11-08
CA3130061A1 (en) 2014-10-09
MX377459B (es) 2025-03-10
BR112015025159A2 (pt) 2017-07-18
KR20220025901A (ko) 2022-03-03
JP2016520551A (ja) 2016-07-14
JP6850783B2 (ja) 2021-03-31
JP2019055968A (ja) 2019-04-11
EP4095146A1 (en) 2022-11-30
AU2020281043C1 (en) 2023-06-01
IL241878B (en) 2021-09-30
EP2988597B1 (en) 2022-06-08
CA2908575A1 (en) 2014-10-09
WO2014165792A3 (en) 2014-12-24
CN111825733A (zh) 2020-10-27
EP2988597A2 (en) 2016-03-02
US11634449B2 (en) 2023-04-25
CA2908575C (en) 2021-11-16
MX2015014026A (es) 2016-08-03
JP7111381B2 (ja) 2022-08-02
AU2014248014A1 (en) 2015-10-22
US20160052951A1 (en) 2016-02-25
KR20150140735A (ko) 2015-12-16
US20180298048A1 (en) 2018-10-18
AU2020281043B2 (en) 2023-02-02
EP2988597A4 (en) 2017-03-08
KR102363621B1 (ko) 2022-02-25
CN105246334A (zh) 2016-01-13
US20220332747A1 (en) 2022-10-20
WO2014165792A2 (en) 2014-10-09
MX2020011518A (es) 2022-10-17
KR102528984B1 (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
JP7111381B2 (ja) マクロライドならびにそれらの調製および使用の方法
US20230109357A1 (en) 14-membered ketolides and methods of their preparation and use
JP2022507776A (ja) Ｃ１０－アルキレン置換された１３員マクロライド及びそれらの使用
HK40085225A (en) Macrolides and methods of their preparation and use
US20220306673A1 (en) Macrolides with Modified Desosamine Sugars and Uses Thereof
HK1225228A1 (en) Macrolides and methods of their preparation and use
HK1225228B (en) Macrolides and methods of their preparation and use
CN119403559A (zh) 林可酰胺及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181114

R150 Certificate of patent or registration of utility model

Ref document number: 6437523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250